Raynaud's phenomenon in mixed connective tissue disease

Research output: Contribution to journalReview articlepeer-review


Raynaud's phenomenon is present almost uniformly in MCTD. Patients who present with Raynaud's phenomenon and a high anti-U1-RNP antibody titer should be watched closely for features of MCTD. In particular, nailfold capillary findings are helpful to distinguish these patients from those who have primary Raynaud's phenomenon. Cardiopulmonary complications, including pulmonary hypertension, are a risk among patients who present with Raynaud's phenomenon and anti-U1-RNP antibodies. Although Raynaud's phenomenon tends to be less severe in patients who have MCTD compared with those who have scleroderma, its pathogenesis seems to be similar. Specific recommendations for therapy for Raynaud's phenomenon in MCTD are not yet established, but it makes sense to follow the management that is used in patients who have scleroderma.

Original languageEnglish (US)
Pages (from-to)465-481
Number of pages17
JournalRheumatic Disease Clinics of North America
Issue number3
StatePublished - Aug 1 2005

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Raynaud's phenomenon in mixed connective tissue disease'. Together they form a unique fingerprint.

Cite this